Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
Bruno R, Hille D, Riva A, et al. J Clin Oncol. 1998;16:187-96
This study demonstrated that it was possible to evaluate docetaxel pharmacokinetics in a large phase II clinical trial to investigate pharmacodynamic relationships. Correlation of docetaxel exposure to both neutropenia and time to progression were found.